21 December 2007 Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 29 November 2007 Results of the 2007 Annual General Meeting 29 November 2007 Annual General Meeting 2007 Chairman's Address 29 November 2007 Annual General Meeting 2007 CEO's Address 29 November 2007 Webcast of CEO Presentation - click here to listen 14 November 2007 Progen to Conduct Global Search for New Directors 9 November 2007 Progen Presents at Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference - click to view and listen mp3 file 5 November 2007 Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at AASLD 3 November 2007 Poster Presentation AASLD - Additional Data Analysis from PI-88 Phase 2 Liver Cancer Study 2 November 2007 Progen to Present at AASLD 2 November 2007 Progen Update on Phase 3 PI-88 Clinical Program 29 October 2007 Progen Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 26 October 2007 Correction to Progen's AGM Meeting Documentation 26 October 2007 Progen's Annual Report 2007 26 October 2007 Progen's AGM Meeting Documentation 2007 23 October 2007 Progen Presents Preclinical Data for Second-Generation Anti-Tumor Compounds at AACR-NCI-EORTC International Conference Click here for a copy of the poster 28 September 2007 Open Briefing®. Progen's CEO on PI-88 Fast Track 24 September 2007 US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 24 September 2007 Progen Announces PI-88 Phase 2 Lung Cancer Results 20 September 2007 Orphan Drug Designation for PI-88 granted in the EU 6 September 2007 Progen Pharmaceuticals Presentation for the Thomas Weisel Partners Healthcare Conference Here is official link to view Progen Pharmaceuticals webcasting page: http://www.veracast.com/webcasts/twp/healthcare07/09203479.cfm 30 August 2007 Progen Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 23 August 2007 Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 23 August 2007 Preliminary Final Report 30 June 2007 21 August 2007 Open Briefing® - Progen Phase 3 Contract Research Organisation 16 August 2007 Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 15 August 2007 EMEA Recommends Orphan Drug Designation for PI-88 25 July 2007 Progen Pharmaceuticals Warrants Approved for Listing on NASDAQ 11 July 2007 Progen Pharmaceuticals Outlines Preliminary Phase 3 Clinical Trial Design 11 July 2007 Progen Pharmaceuticals Progress Update 11 July 2007 Presentation 29 June 2007 Progen Pharmaceuticals Establishes Leading International Clinical Advisory Board of Liver Cancer Specialists 27 June 2007 Progen Pharmaceuticals Allots Share and Options 20 June 2007 Progen Pharmaceuticals raises A$34.1m in Entitlements Offer 13 June 2007 Progen Pharmaceuticals to present the Bell Potter Emerging Companies Conference Click here for the presentation 12 June 2007 Progen Pharmaceuticals to present at Annual Needham & Co Conference Here is official link to view Progen Pharmaceuticals webcasting page: http://www.wsw.com/webcast/needham18/pgla/ 8 June 2007 Progen Expands Senior Management Team 11 May 2007 Progen Receives $4.6M in P3 Grant Funding 10 May 2007 Open Briefing - Progen Pharmaceuticals CEO on Capital Raising 10 May 2007 Australian Entitlement Offer Prospectus 10 May 2007 Key Dates for Entitlements Offer 10 May 2007 Progen Pharmaceuticals Commences Entitlements Offer 9 May 2007 Progen Pharmaceuticals Completes Share Placement 3 May 2007 Progen Pharmaceuticals Announces Fundraising Activities 15 April 2007 Phase 2 Liver Cancer Trial Exceeds Efficacy Expectation 15 April 2007 Clinical Appendix - Detailed Phase II Liver Cancer Trial Analysis 29 March 2007 Offical Name Change to Progen Pharmaceuticals Limited 16 March 2007 General Meeting Results 16 March 2007 General Meeting Chairman's Address 16 March 2007 General Meeting CEO's Presentation 14 March 2007 Amendment to General Meeting Agenda 12 March 2007 PI-88 Data to be Presented at Key International Conferences 21 February Progen ends the half year prepared to bolster its financial foundation for proceeding towards PI-88 registration 21 February 2007 Appendix 4D 15 February 2007 Progen - Notice of General Meeting 5 February 2007 Progen SPP exceeds expectations with $5.4 million raised 16 January 2007 Progen buys back PI-88 royalty obligation from Medigen